N	Concordance
1	- Malignant melanoma and adjuvant alpha interferon-2b for patients at high      
2	f a short course of ribavirin and alpha interferon in the treatment of chronic a
3	Modulation of chemosensitivity by alpha interferon in multiple myeloma       and
4	 and economic outcomes of current alpha interferon treatment regimens remains li
5	 The in vitro effect of leukocyte alpha interferon on human myeloma cells in a s
6	binding protein or IRF-7, a novel alpha interferon-inducible factor identified i
7	g different regimens and forms of alpha interferon in different cohorts of patie
8	 wide array of adverse effects of alpha interferon have been described. Several 
9	cities associated with the use of alpha interferon in current doses and  schedul
10	he best obtained with recombinant alpha interferon. The optimal treatment regime
11	nts with nonsustained response to alpha interferon alone, because the majority o
12	s progress include treatment with alpha interferon and stem cell transplantation
13	r more months of subcutaneous alpha(2a)-interferon (3 mU/m2) was prospectively e